Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Covington
Cipla
Queensland Health
US Department of Justice
Merck
Boehringer Ingelheim
Colorcon
Dow
Fish and Richardson
Daiichi Sankyo

Generated: October 21, 2017

DrugPatentWatch Database Preview

Eli Lilly Co Company Profile

« Back to Dashboard

What is the competitive landscape for ELI LILLY CO, and when can generic versions of ELI LILLY CO drugs launch?

ELI LILLY CO has two approved drugs.

There are four US patents protecting ELI LILLY CO drugs.

There are two hundred and seventy-nine patent family members on ELI LILLY CO drugs in fifty-four countries and sixteen supplementary protection certificates in ten countries.

Summary for Applicant: Eli Lilly Co

International Patents:279
US Patents:4
Tradenames:2
Ingredients:2
NDAs:2
Drug Master File Entries: (click here to view)1
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eli Lilly Co
ADCIRCA
tadalafil
TABLET;ORAL022332-001May 22, 2009RXYesYes► Subscribe► SubscribeY ► Subscribe
Eli Lilly Co
ADCIRCA
tadalafil
TABLET;ORAL022332-001May 22, 2009RXYesYes► Subscribe► SubscribeYY ► Subscribe
Eli Lilly Co
ZYPREXA RELPREVV
olanzapine pamoate
SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR022173-003Dec 11, 2009RXYesYes► Subscribe► SubscribeYY ► Subscribe
Eli Lilly Co
ADCIRCA
tadalafil
TABLET;ORAL022332-001May 22, 2009RXYesYes► Subscribe► SubscribeYY ► Subscribe
Eli Lilly Co
ZYPREXA RELPREVV
olanzapine pamoate
SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR022173-002Dec 11, 2009RXYesNo► Subscribe► SubscribeYY ► Subscribe
Eli Lilly Co
ZYPREXA RELPREVV
olanzapine pamoate
SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR022173-001Dec 11, 2009RXYesNo► Subscribe► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Eli Lilly Co

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Eli Lilly Co
ZYPREXA RELPREVV
olanzapine pamoate
SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR022173-001Dec 11, 2009► Subscribe► Subscribe
Eli Lilly Co
ZYPREXA RELPREVV
olanzapine pamoate
SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR022173-003Dec 11, 2009► Subscribe► Subscribe
Eli Lilly Co
ZYPREXA RELPREVV
olanzapine pamoate
SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR022173-002Dec 11, 2009► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for ELI LILLY CO drugs

Drugname Dosage Strength Tradename Submissiondate
tadalafil
Tablets20 mg
ADCIRCA
10/15/2009

Non-Orange Book Patents for Eli Lilly Co

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,143,746 Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use► Subscribe
5,981,527 Cyclic GMP-specific phosphodiesterase inhibitors► Subscribe
6,784,179 Tetracyclic derivatives, process of preparation and use► Subscribe
6,617,321 2-methyl-thieno-benzodiazepine formulation► Subscribe
6,127,542 Tetracyclic derivatives, process of preparation and use► Subscribe
6,140,329 Use of cGMP-phosphodiesterase inhibitors in methods and compositions to treat impotence► Subscribe
6,369,059 Tetracyclic derivatives, process of preparation and use► Subscribe
6,025,494 Tetracyclic derivatives, process of preparation and use► Subscribe
6,608,065 Use of cGMP phosphodiesterase inhibitors in methods to treat female sexual dysfunction► Subscribe
6,841,167 .beta.-carboline pharmaceutical compositions► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Eli Lilly Co Drugs

Country Document Number Estimated Expiration
Poland185737► Subscribe
Australia776722► Subscribe
Algeria3180► Subscribe
New Zealand516616► Subscribe
Australia7391298► Subscribe
Colombia5200849► Subscribe
Australia702324► Subscribe
Eurasian Patent Organization004872► Subscribe
Czech Republic302367► Subscribe
Norway980153► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Eli Lilly Co Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0012Belgium► SubscribePRODUCT NAME: OLANZAPINE; REGISTRATION NO/DATE: EU/1/96/022/001 19960927
C/GB96/058United Kingdom► SubscribePRODUCT NAME: OLANZAPINE OPTIONALLY IN THE FORM OF AN ACID ADDITION SALT; REGISTERED: UK EU/1/96/022/001 19960927; UK EU/1/96/022/002 19960927; UK EU/1/96/022/003 19960927; UK EU/1/96/022/004 19960927; UK EU/1/96/022/005 19960927; UK EU/1/96/022/006 19960927; UK EU/1/96/022/007 19960927; UK EU/1/96/022/008 19960927; UK EU/1/96/022/009 19960927; UK EU/1/96/022/010 19960927
2003001Lithuania► SubscribePRODUCT NAME: TADALAFILUM ((6R,12AR)-2,3,6,7,12,12A-HEKSAHIDRO-2-METIL-6-(3,4-METILENDIOKSIFENIL)-PIRAZINO(2',1':6,1)PIRIDO(3,4-B)INDOL-1,4-DIONAS); REGISTRATION NO/DATE: 03/8034/3, 03/8035/3 20030328
2016 00024Denmark► SubscribePRODUCT NAME: AMBRISENTAN USED IN COMBINATION TREATMENT WITH TADALAFIL; REG. NO/DATE: EU/1/08/451 (001-004) 20151125
0124Netherlands► Subscribe300124, 20150119, EXPIRES: 20171111
70015Netherlands► SubscribePRODUCT NAME: OLANZAPINE, DESGEWENST IN DE VORM VAN EEN ZUURADDITIEZOUT; REGISTRATION NO/DATE: EU/1/96/022/001 - EU/1/96/022/010 19960927
2003001,C0740668Lithuania► SubscribePRODUCT NAME: TADALAFILUM ((6R,12AR)-2,3,6,7,12,12A-HEKSAHIDRO-2-METIL-6-(3,4-METILENDIOKSIFENIL)-PIRAZINO(2',1':6,1)PIRIDO(3,4-B)INDOL-1,4-DIONAS); REGISTRATION NO/DATE: 03/8034/3, 03/8035/3 20030328
081Luxembourg► SubscribePRODUCT NAME: AMBRISENTAN UTILISE EN TRAITEMENT COMBINE AVEC TADALAFIL; FRIST REGISTRATION: 20151125
C/GB03/007United Kingdom► SubscribePRODUCT NAME: TADALAFIL AND PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS AND SOLVATES THEREOF.; REGISTERED: UK EU/1/02/237/001-004 20021114
0813Netherlands► SubscribePRODUCT NAME: AMBRISENTAN TOEGEPAST IN COMBINATIEBEHANDELING MET TADALAFIL; REGISTRATION NO/DATE: EU/1/08/451 (C(2008) 1637) 20151125
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Fuji
Novartis
Chubb
Express Scripts
Cerilliant
Citi
Deloitte
McKinsey
Cantor Fitzgerald
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot